Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by Bird & BirdMax Walters joins Sally Shorthose and James Baillieu of Bird & Bird and Henry Hadad of Bristol Myers Squibb to discuss how COVID-19 has shaped transactional work -
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021
-
Sponsored by MaiwaldChristian Meyer of Maiwald explores a recent decision which prevents the distribution of medicinal products by means of an automatic dispenser from a foreign mail-order pharmacy
-
Sponsored by Liu, Shen & AssociatesXiaoming Zhang of Liu Shen & Associates takes a closer look at the Draft for Comments to the Patent Examination Guidelines and discusses its positive approach towards AI-related applications
-
Sponsored by Vivien Chan & CoExperts from Vivien Chan & Co report on significant developments from the IP world across China and the Asia-Pacific
-
Sponsored by Griffith HackKaren Sinclair and Sarah Cox of Griffith Hack review the Australian federal government’s budget measures for R&D, innovation, and medical technology funding
